10-K: Aditxt Faces Going Concern Doubt Amidst Significant Losses

Aditxt, Inc. reports substantial net losses and negative cash flow for fiscal year 2025, raising significant doubt about its ability to continue as a going concern, despite ongoing product development and capital raising efforts.

Summary

• The company reported a net loss of $42,787,043 for the fiscal year ended December 31, 2025, an increase from $35,020,058 in 2024.
• Revenue decreased dramatically to $3,195 in 2025 from $133,985 in 2024, primarily due to decreased COVID testing.
• As of December 31, 2025, the cash balance was $3,198,599, and the accumulated deficit reached $209,808,770.
• Management explicitly stated that remaining funds are not sufficient to fund operations for the next 12 months, creating substantial doubt about the company's ability to continue as a going concern.
• The company is non-compliant with Nasdaq Listing Rule 5550(b)(1) requiring a minimum of $2,500,000 in stockholders' equity and received a delisting notice, though an extension was granted until May 15, 2026.
• The common stock traded below $1.00 for 6 consecutive trading days as of March 30, 2026, risking a minimum bid price deficiency, and its market capitalization was approximately $713,000, well below a proposed Nasdaq delisting threshold of $5.0 million.
• The merger agreement with Evofem Biosciences, Inc. was terminated on October 20, 2025, due to the end date passing and failure to obtain shareholder approval, though Aditxt retains its holdings of Evofem F-1 Preferred Stock, convertible notes, and warrants.
• The Appili Arrangement Agreement was terminated effective May 31, 2025, resulting in a $1,250,000 termination fee, with $750,000 remaining unpaid as of December 31, 2025.
• The company is developing ADI-100, an immune modulation therapeutic, with preclinical studies completed and human trials for Stiff Person Syndrome expected to begin in 2026.
• Pearsanta, a subsidiary, is developing molecular tests based on mitochondrial DNA for early detection of various cancers (prostate, endometriosis, ovarian, lung, pancreatic, liver, breast, stomach, esophageal, and colorectal).
• Pearsanta acquired patents related to Adductomics Technology on March 21, 2025, for comprehensive assessment of DNA adducts.
• On March 11, 2026, the company acquired Ignite Proteomics, LLC for 36,000 shares of newly created Series A-2 Convertible Preferred Stock, valued at $36,000,000.
• Multiple reverse stock splits were effectuated: 1-for-40 (Oct 2024), 1-for-250 (Mar 2025), 1-for-113 (Nov 2025), and 1-for-8 (Mar 2026).
• Material weaknesses in internal control over financial reporting were identified, including inadequate documentation of accounting policies and insufficient procedures for accounts payable and debt/equity transactions.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to significant and increasing net losses, plummeting revenue, severe liquidity issues, explicit going concern doubt, and multiple Nasdaq delisting threats, despite some progress in product development and capital raising.

Positives

• Preclinical studies for ADI-100, an immune modulation therapeutic, have been completed, providing data supporting its potential effectiveness and safety.
• Good Manufacturing Practices (GMP) clinical-grade drug substances for ADI-100 have been successfully manufactured.
• Adimune is engaged with regulatory agencies in Germany and the Mayo Clinic to advance ADI-100 clinical trials, with a human trial for Stiff Person Syndrome expected to get underway in 2026.
• Pearsanta, a subsidiary, acquired the Mitomic Technology platform and Adductomics Technology patents, positioning it for research and development of mtDNA-based biomarkers for early disease detection.
• Pearsanta operates a state-of-the-art, CLIA-certified, CAP-accredited, and NYS CLEP-approved laboratory facility in Richmond, VA.
• The company acquired Ignite Proteomics, LLC on March 11, 2026, expanding its portfolio into proteomics.
• Stockholders approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 350,000 shares.
• Nasdaq granted an extension until May 15, 2026, for the company to regain compliance with its listing rules regarding stockholders' equity.

Negatives

• Net loss increased to $42,787,043 in 2025 from $35,020,058 in 2024.
• Revenue plummeted to $3,195 in 2025 from $133,985 in 2024, a 97.6% decrease, primarily due to decreased COVID testing.
• Negative cash flow from operating activities of $25,688,359 in 2025.
• Accumulated deficit reached $209,808,770 as of December 31, 2025.
• Management and auditors express substantial doubt about the company's ability to continue as a going concern.
• The company is non-compliant with Nasdaq Listing Rule 5550(b)(1) for stockholders' equity and faces potential delisting.
• Common stock traded below $1.00 for 6 consecutive days as of March 30, 2026, risking a minimum bid price deficiency, and its market capitalization was approximately $713,000.
• The company is in default on its Richmond, VA lease due to an outstanding security deposit of $159,375.
• The merger agreement with Evofem Biosciences, Inc. was terminated due to the end date passing and failure to obtain shareholder approval.
• The Appili Arrangement Agreement was terminated, incurring a $1,250,000 termination fee, with $750,000 remaining unpaid as of December 31, 2025.
• Material weaknesses in internal control over financial reporting were identified, leading to corrected material misstatements in financial statements.
• An outstanding redemption payable of $1,030,667 for Series C-1 Convertible Preferred Stock existed as of December 31, 2025.
• The May 2025 Note was in default status as of December 31, 2025.
• The January Loan Agreement was in technical default as of December 31, 2025.
• A legal proceeding was initiated by Vertalo, Inc. on February 3, 2026, seeking alleged unpaid fees of $300,000, warrants, and at least $500,000 in damages.

Risks

• The company's financial situation creates substantial doubt about its ability to continue as a going concern.
• The ability to remain compliant with Nasdaq Capital Market listing requirements is uncertain, risking delisting.
• The company has generated no significant revenue from commercial sales to date, and future profitability is uncertain.
• Failure to obtain necessary capital to fund operations will prevent product development, leading to likely loss of investment.
• Additional funding may not be available on acceptable terms or at all, potentially leading to dilution for existing shareholders.
• The regulatory approval process for product candidates is expensive, time-consuming, and uncertain.
• Substantial delays in completing clinical studies may occur, requiring additional costs or failure to demonstrate adequate safety and efficacy.
• Unsuccessful future pre-clinical development and clinical Phase I/II studies could prevent regulatory approval or commercialization.
• Even with regulatory approval, successful commercialization and revenue generation for product candidates may be limited.
• Adverse events involving products could lead to FDA delays, denials, or product recalls, harming reputation and financial results.
• Certain technologies are subject to revocable licenses from Loma Linda University and Stanford if payment and milestone deadlines are not met.
• Loss of CLIA certification or state laboratory licenses would prevent the company from offering its assays and harm its business.
• Royalty and milestone payments to third parties will affect results of operations.
• The company faces substantial competition in the development and commercialization of drugs.
• Technologies and products under development may fail to be successfully commercialized and generate significant revenues.
• Customers may not adopt the company's products quickly or at all.
• Failure to obtain or maintain patents, licensing agreements, and other intellectual property could materially impact competitive ability.
• Some intellectual property may be subject to march-in rights by the U.S. federal government, limiting exclusive rights.
• The company does not expect to pay dividends in the foreseeable future.
• Future sales or issuances of substantial amounts of common stock, including for acquisitions or strategic transactions, could result in significant dilution.
• The company's acquisition strategy exposes it to substantial risks, including due diligence failures, over-paying, and integration difficulties.
• Difficulty in effectively integrating and managing acquired businesses could drain resources and disrupt ongoing operations.
• Acquisitions may result in significant accounting charges that adversely affect earnings.
• Planned acquisitions may result in unexpected consequences to the business and results of operations.
• Failure to manage a growing and changing business could have a material adverse effect.
• Competition for acquisition targets may lead to sub-optimal prices or missed opportunities.
• Inability to successfully fund acquisitions due to unavailability of equity or debt financing on acceptable terms.
• Management and acquisition strategies may change without stockholder consent, potentially leading to riskier business activities.
• Future credit facilities may expose the company to additional risks associated with leverage and inhibit operating flexibility.
• The company may be deemed an investment company under the Investment Company Act if it ceases to control and operate its businesses.
• Intangible assets and goodwill recorded in connection with acquisitions may become impaired, leading to significant charges against earnings.
• Lawsuits to protect or enforce intellectual property rights are expensive, time-consuming, and may be unsuccessful.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights.
• Failure to pay periodic maintenance fees and annuities on issued patents could result in loss of patent rights.
• Claims by third parties asserting misappropriation of intellectual property or ownership of the company's intellectual property.
• Reliance on information technology carries risks of service interruptions, data corruption, cyber-based attacks, or network security breaches.
• Claims, litigation, government investigations, product liability, and recalls may adversely affect the business.
• The company must successfully manage compliance with current and expanding laws and regulations, including ESG matters.
• Anti-takeover provisions under Delaware law could discourage, delay, or prevent a change in control.
• The company could issue blank check preferred stock without stockholder approval, diluting interests and impairing voting rights.
• Provisions in charter documents and Delaware law could discourage takeovers.
• The exclusive forum provision in the Amended and Restated Certificate of Incorporation could limit stockholders' ability to obtain a favorable judicial forum.
• The company no longer qualifies as an emerging growth company as of January 1, 2026, increasing disclosure requirements.
• As a smaller reporting company, reduced disclosure requirements may make it difficult to compare performance with other public companies.

Future Outlook

The company expects to incur additional net expenses and significant operating losses for the foreseeable future and believes its current cash reserves are insufficient to fund operations for the next 12 months, necessitating significant additional capital. Clinical trials for ADI-100 are planned for 2026, and Pearsanta anticipates further development of its Adductomics platform over the next two to three years toward clinical and commercial applications.

Management Comments

• "We believe the world needs—and deserves—a new approach to innovation that harnesses the power of large groups of stakeholders who work together to ensure that the most promising innovations reach people who need them most."
• "The socialization of innovation through engaging stakeholders in every aspect of it, is key to transforming more innovations, more rapidly, and more efficiently."
• "Our management believes that the unique structural and functional characteristics of mtDNA, and more specifically mutated mtDNA, render it a biological system suitable for biomarker identification, early disease detection, monitoring, risk assessment, and therapeutic targeting."
• "We believe that empowering women with innovative, science-driven solutions remains an important and timely priority in global healthcare."
• "We believe our remaining funds on hand will not be sufficient to fund our operations for the next 12 months and such creates substantial doubt about our ability to continue as a going concern beyond one year."

Industry Context

StockSavvy.ai notes that Aditxt operates in highly competitive and capital-intensive sectors of biotechnology, including immune modulation and early cancer diagnostics. The company's strategy of acquiring and developing multiple health innovations, while ambitious, faces significant challenges given its limited revenue generation and substantial operating losses, which are not uncommon for early-stage biotech firms but are exacerbated by ongoing Nasdaq compliance issues. The termination of the Evofem merger and Appili agreement highlights difficulties in executing strategic transactions in this volatile market.

Comparison to Industry Standards

• Aditxt's ADI technology, using in-body induction of apoptosis to promote tolerance, is stated to be unique compared to groups promoting tolerance through cell therapies and ex vivo manipulation.
• Pearsanta's Mitomic Prostate Test aims to address the challenge of over-diagnosis in prostate cancer, where up to 50% of men are over-diagnosed, and treatment risks for low-grade cancers often outweigh benefits, indicating a significant unmet need in urology diagnostics.
• The Mitomic Endometriosis Test targets a condition affecting approximately 1 in 10 women, where diagnosis typically takes ten years, and over 90% of diagnosed patients have moderate to severe symptoms, highlighting a high clinical need for earlier detection.
• The company's financial performance, with increasing net losses and minimal revenue, significantly lags behind established biotech companies that have successfully commercialized products, such as Exact Sciences (Cologuard for cancer screening) or Vertex Pharmaceuticals (cystic fibrosis drugs), which demonstrate robust revenue streams and positive cash flows.

Management Changes

Corporate Governance

Legal Proceedings

• On February 3, 2026, Vertalo, Inc. filed an Original Petition against Aditxt, Inc. in the District Court of Travis County, Texas, asserting claims for breach of contract and seeking alleged unpaid fees of $300,000, warrants to acquire 6,250 shares of Aditxt common stock, $26,000 of alleged travel-related costs, additional alleged damages of at least $500,000, attorneys' fees, and interest. Aditxt disputes the allegations and intends to defend the matter vigorously, pursue counterclaims and available claims and defenses.

Related Party Transactions

• On May 22, 2025, Amro Albanna, the Chief Executive Officer, loaned $233,000 to the company, which was fully paid off by December 31, 2025.
• On February 15, 2024, Amro Albanna, the Chief Executive Officer, loaned $205,000 to the company, which was fully paid off by December 31, 2025.
• On June 6, 2025, Shahrokh Shabahang, the Chief Innovation Officer, loaned $70,000 to the company, which was fully paid off by December 31, 2025.
• On June 20, 2025, Amro Albanna, the Chief Executive Officer, loaned $90,000 and Shahrokh Shabahang, the Chief Innovation Officer, loaned $100,000 to the company, which were fully paid off by December 31, 2025.
• On August 13, 2025, Amro Albanna, the Chief Executive Officer, loaned $95,000 and Shahrokh Shabahang, the Chief Innovation Officer, loaned $90,000 to the company, which were fully paid off by December 31, 2025.
• Rowena Albanna, the Chief Operating Officer, is the wife of Amro Albanna, the Chief Executive Officer.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing capital raises and frequent reverse stock splits. The risk of delisting from Nasdaq could severely reduce liquidity and market price, potentially leading to a substantial or total loss of investment.
• Employees are currently considered to have good relations with the company, but the financial instability and going concern doubt could impact job security and morale.
• Customers may benefit from the development of new diagnostic and therapeutic products, but the adoption and commercial success of these products remain uncertain. The significant decrease in revenue from COVID testing indicates vulnerability to market shifts.
• Creditors face increased risk as the company is in default on some loan agreements and a lease, indicating potential challenges in meeting financial obligations.
• Regulatory authorities are engaged in the product approval process, but delays in clinical trials and ongoing Nasdaq compliance issues highlight operational and governance challenges.

Next Steps

• Regain compliance with Nasdaq listing rules by May 15, 2026.
• Submit a publicly available report to the SEC and Nasdaq by May 15, 2026, detailing the compliance plan.
• Initiate human trials for Stiff Person Syndrome with Mayo Clinic in 2026.
• Advance the Adductomics platform toward clinical and commercial applications over the next two to three years.
• Obtain an extension for the LLU milestone payment due September 30, 2024.
• Actively pursue an extension for the completion of first-in-human (Phase I/II) clinical trials by September 30, 2024.
• Complete Phase III clinical trials for ADI technology by September 30, 2026 (LLU milestone).
• Obtain Biologic Licensing Approval (BLA) by the FDA by September 30, 2027 (LLU milestone).
• Remediate identified material weaknesses in internal control over financial reporting.
• Defend against the Vertalo, Inc. lawsuit and pursue counterclaims.
• Continue capital raising transactions to fund operations and product development.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by increasing net losses, near-zero revenue, negative working capital, and explicit "going concern" doubt from management and auditors. Multiple Nasdaq delisting threats, including a market capitalization significantly below proposed thresholds, indicate imminent risk to public trading. While there are ongoing R&D efforts and recent acquisitions, the company's inability to generate significant revenue or secure stable financing, coupled with material weaknesses in internal controls and ongoing litigation, presents an extremely high-risk profile. The frequent reverse stock splits are a clear sign of a failing stock price and are typically followed by further declines. Investors face a high probability of substantial or total loss of capital.

Keywords

Biotechnology, Immunotherapy, Cancer Diagnostics, Going Concern, Nasdaq Delisting, Financial Losses, Capital Raise, Clinical Trials, Autoimmune Diseases, SEC Filing, 10-K, ADI-100, Mitomic Technology, Adductomics, Evofem Biosciences, Ignite Proteomics, Medical Devices, Diagnostics, Life Sciences, Reverse Stock Split